Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term extension study of odevixibat in Alagille syndrome after ASSERT
NL-OMON60577Phase 3Completed
- Sponsor
- Ipsen
- Start
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of odevixibat in Alagille syndrome (ALGS), sponsored by Ipsen. Primary endpoint: Change from baseline in scratching through Week 72. Started May 2022; status: completed.
02
Drugs
odevixibat
03
Conditions
Alagille syndrome (ALGS)
Beyond the preview
Go deeper on NL-OMON60577.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60577.